Skip to main content

Table 2 QoL assessments at 3rd and 6th months

From: Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

 

3rd month QoL change %

6th month QoL change %

Gemcitabine

Gemcitabine + nab-Paclitaxel

p

Gemcitabine

Gemcitabine + nab-Paclitaxel

p

Mean

Mean

Mean

Mean

Functional scales

Cognitive functioning

−8.8

23.8

0.048

21

22.5

0.387

Emotional functioning

12.9

50.8

0.048

0.6

37.8

0.851

Physical functioning

−11.7

12.8

0.051

−4.9

5.7

0.761

Role functioning

2.9

17.4

0.039

42.3

10.9

0.456

Social functioning

−1.6

30.4

0.024

7.5

3.9

0.743

Symptom scales

Appetite loss

−12.5

−14.4

0.226

−13.3

− 15

0.771

Constipation

14.1

25.9

0.706

22.9

8.6

0.888

Diarrhea

2.6

17.6

0.558

16.9

−1.4

0.707

Dyspnea

−32.6

−7.4

0.172

11

−17.6

0.206

Fatigue

60.4

5.9

0.027

−51.4

−30.4

0.924

Financial difficulties

−11

12.1

0.077

−13.8

12.8

0.879

Insomnia

−19

11

0.141

−9.6

7.7

0.276

Nausea-vomiting

−4.1

12

0.559

−0.6

−0.8

0.898

Pain

−13.8

12.4

0.142

−11.3

− 16.6

0.514

Global health status/QoL

12.7

8

0.163

70.6

−9.2

0.158